Mylan Institutional LLC recalled 800 vials of Haloperidol Lactate Injection on October 10, 2025, due to incorrect RFID tag labels. The product may pose a risk due to potential mislabeling affecting tracking and administration. Healthcare providers should stop using the product immediately and follow up with Safecor Health for guidance.
Labeling: Not Elsewhere Classified:Incorrect RFID tag labels applied to product by repackaging firm.
Consumers and healthcare providers should stop using this product immediately. Contact Safecor Health, LLC or your healthcare provider for guidance. Notification method: E-Mail
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves Haloperidol Lactate Injection, 5 mg/mL, packaged in 25 x 1 mL single-dose vials. The affected lot numbers are 25381993 and 25391516, with an expiration date of December 31, 2026. The product was distributed in Massachusetts.
The recall stems from incorrect RFID tag labels applied by a repackaging firm. This mislabeling could lead to medication errors, potentially impacting patient safety.
No specific incidents or injuries linked to this recall have been reported. The issue primarily relates to potential tracking and administration errors.
Stop using Haloperidol Lactate Injection immediately. Contact Safecor Health, LLC or your healthcare provider for further guidance. Notifications will primarily be sent via email.
For assistance, reach Safecor Health, LLC via email at their official website. Additional guidance may be obtained from healthcare providers.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.